Elite Pharmaceuticals Inc (ELTP)

[elichen]

IF YOU WANT REAL FACTS ABOUT ELTP
Newbies and scared Longs, just read or re-read Post #86489 from Couch on 1/23/2014 (copies below) and take a deep breath, knowing you've got a great investment here:

If you've read through the two seeking alpha articles you went to the right place! Excellent overview of where the company has come from and where it is headed IMO. Both 5 star DD articles. I'll include a few other links at the end of this post that I think would be helpful as well.

No question uplisting to a larger exchange would be nothing but helpful to this company. The previous CEO and current chairman of the board Jerry Treppel addressed this very question about a year and a half ago. He said the Nasdaq is the next exchange and goal for Elite. The stock used to trade on the Amex under the symbol ELI with an average PPS of $4 and an all time high of $22.50 ~~ a very long time ago. Previous management ran the company into the ground with R&D costs and brought in little to no revenue except a line of lodrane products (3) that got pulled by the FDA in 2011 ~~~ just after I started buying my first shares in March 2011. The company delisted from the Amex to the OTC somewhere around April of 2009. Their abuse resistant technology (ART) has always been solid and although previous trials were nothing but successful ~~ they were a long time ago. Thus the renewed interest (2013-14) in the stock once the current CEO Nasrat Hakim renewed studies on their signature technology and what the company was founded on. Starting trials and Nasrat Hakim becoming CEO after leaving Actavis is what all the fuss is about recently. No hot air inflationary articles to be found. Just the opposite if you look around a little.

Sustainable?? The stock ran from .12 into the high .30's on very little news except the company starting FDA ART studies. What everyone is waiting on is positive FDA study news. That comes and IMO this rally is more than sustainable. Short run ~~ Maybe a pullback ~~ to what number not my cup of tea predicting PPS. I'll let a few of the other numbers folks speculate on how high ~~ I was told by the CEO himself $4 dollars is easily attainable with one ART product on the market ~~ won't come till 2015 though! This isn't a flash in the pan ~~ look at their website and see how many products the company now has out compared to where it was in 2011. Zero in 2011 and now 8 with 12 approved products pending site approval. That will take awhile to do. And the company has about 2 -3 times the amount of shares now then when I started buying. And they have some debt maybe 2 -4 million. But the company's upcoming Quarterly is do out Feb. 14 ~ should be the highest in the company's history. The company almost went of business in 2011 ~ but the company is a long ways away from 2011. Patents plural now in place, better management team, new CEO, funding for ART trials in place and the company is talking to Big Pharma about a possible deal in relation to ART trials.

Price target ~ I believe the CEO when he told me $4 is attainable ~ When? When the company puts out their first ART product and garners revenue off of it ~~~ as I have told anyone who will listen. 1 - 3 years before the real money here....and that is why you invest now....before the ART trials!!!

Any further questions throw them out. Its a great board here beyond the mentioned fog and your questions will be answered to the best of our ability.

Best,
Couch

http://www.earningsimpact.com/Transcript/84596/ELTP/Q2-2014-Earnings-Call#sthash.haOC8eH8.S4dFOaM9.dpbs

http://seekingalpha.com/article/1203841-elite-pharmaceuticals-ceo-discusses-f3q13-results-earnings-call-transcript

http://www.elitepharma.com/investor_relations.asp?goto=369

http://biz.yahoo.com/e/131114/eltp10-q.html

http://www.elitepharma.com/resources/Elite.pdf

http://seekingalpha.com/instablog/4199131-couch/1941422-elite-pharmaceuticals-eltp-intellectual-property-ip-and-the-right-to-devise-a-better-pain-killer

http://www.businesswire.com/news/home/20110412007011/en/Research-Markets-Chronic-Pain-Therapeutics-Market-Forecast#.UuHNKeD0BD0

http://www.prlog.org/11462476-osteoarthritis-oa-pain-therapeutics-pipeline-assessment-and-market-forecasts-to-2017.html

http://www.elitepharma.com/product_pipeline.asp